Upstream Bio to Participate in Upcoming December Investor Conferences
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Upstream Bio (Nasdaq: UPB) announced that CEO Rand Sutherland, MD will participate in two investor conferences in December 2025: a fireside chat at the Piper Sandler 37th Annual Healthcare Conference in New York on Tuesday, December 2, 2025 at 4:30 p.m. ET, and a fireside chat at the 8th Annual Evercore Healthcare Conference in Miami on Thursday, December 4, 2025 at 10:25 a.m. ET.
Live webcasts will be available under the Events tab on the Investors section of Upstream Bio’s website on the day of each presentation, and replays will be posted after the events.
Details
News Market Reaction – UPB
On Nov 25, the day this news came out, UPB closed 10.67% above the previous close. That session’s volume was 1.6x the stock’s average daily volume.
Data tracked by StockTitan Argus for the Nov 25 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, Chief Executive Officer of Upstream Bio, will be participating in the following upcoming investor conferences in December:
- Piper Sandler 37th Annual Healthcare Conference, New York, NY
Tuesday, December 2, 2025, Fireside Chat – 4:30 p.m. ET - 8th Annual Evercore Healthcare Conference, Miami, FL
Thursday, December 4, 2025, Fireside Chat – 10:25 a.m. ET
Live webcasts of the presentations will be available under the Events tab on the Investors section of Upstream Bio’s website on the day of the event. A replay of the webcasts will be posted on the Company's website following the presentations.
About Upstream Bio
Upstream Bio is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. Upstream Bio is developing verekitug, the only known antagonist currently in clinical development that targets the receptor for thymic stromal lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. Upstream Bio has advanced this highly potent monoclonal antibody into separate Phase 2 trials for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP), severe asthma and chronic obstructive pulmonary disease (COPD). Upstream Bio’s team is committed to maximizing verekitug’s unique attributes to address the substantial unmet needs for patients underserved by today’s standard of care. To learn more, please visit www.upstreambio.com.
Investor and Media Contact:
Meggan Buckwell
Director, Corporate Communications and Investor Relations
ir@upstreambio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.